

Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to *de novo* acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients

Ibrahim Aldoss,¹ Tracey Stiller,² Ni-Chun Tsai,² Joo Y. Song,³ Thai Cao,^{1,4} N. Achini Bandara,¹ Amandeep Salhotra,¹ Samer Khaled,¹ Ahmed Aribi,¹ Monzr M. Al Malki,¹ Matthew Mei,¹ Haris Ali,¹ Ricardo Spielberger,^{1,4} Margaret O'Donnell,¹ David Snyder,¹ Thomas Slavin,⁵ Ryotaro Nakamura,¹ Anthony S. Stein,¹ Stephen J. Forman,¹ Guido Marcucci¹ and Vinod Pullarkat¹

¹Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte; ²Department of Information Sciences, Division of Biostatistics, City of Hope, Duarte; ³Department of Pathology, City of Hope, Duarte; ⁴Kaiser Permanente, Department of BMT, Southern California Medical Group, Los Angeles and ⁵Department of Medical Oncology, Division of Clinical Genetics, City of Hope, Duarte, CA, USA

©2018 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2018.193599

Received: March 19, 2018.

Accepted: June 8, 2018.

Pre-published: June 14, 2018.


Correspondence: ialdoss@coh.org

Supplemental table 1. Factors associated with overall survival in t-ALL patients

	Number of patients	Number of events	Odds Ratio	95% CI	P-value
Age at ALL diagnosis	85	49	1.01	0.98-1.07	0.43
Prior Therapy					0.44
Chemo	32	16	-	-	
Radiation	23	14	1.50	0.59-3.80	0.40
Chemo/Radiation	30	19	1.74	0.75-4.04	0.20
Cytogenetic Group					0.51
NK	15	11	-	-	
Ph+	27	15	0.93	0.38-2.26	0.87
MLL	15	7	0.97	0.32-2.98	0.96
Complex	5	4	1.57	0.46-5.34	0.47
Other/Unknown	23	12	1.11	0.46-2.69	0.82
Prior disease					
Solid Cancer	52	29	-	-	
Blood Cancer	33	20	1.29	0.61-2.73	0.51
HCT (time dependent)					
No	41	26	-	-	
Yes	44	23	0.49	0.22-1.07	0.07

NK: normal karyotype; Ph+: Philadelphia chromosome positive; MLL: mixed lineage leukemia

Supplemental figure 1. Non-relapse mortality for t-ALL and de novo ALL patients who underwent allogeneic HCT



Supplemental figure 2. Survival of de novo and t-ALL patients who did not undergo allogeneic HCT during ALL therapy

